PTC Therapeutics shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Equal-Weight and raised its price target from $28 to $30.
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics shares surged following an upgrade by Morgan Stanley from Underweight to Equal-Weight and an increase in the price target from $28 to $30.
April 29, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PTC Therapeutics stock price is likely to experience a positive short-term impact following Morgan Stanley's upgrade and raised price target.
Upgrades by prominent financial institutions like Morgan Stanley typically lead to increased investor confidence and can drive up the stock price in the short term. The raise in price target further supports a positive outlook for PTCT, suggesting that the stock may have been undervalued at its previous level.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100